- Trials with a EudraCT protocol (28,934)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28,934 result(s) found for: Informed consent.
Displaying page 5 of 1,447.
EudraCT Number: 2011-001699-20 | Sponsor Protocol Number: 042011 | Start Date*: 2012-05-18 |
Sponsor Name:St. Anna Kinderkrebsforschung, GmbH | ||
Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS | ||
Medical condition: Langerhans cell histiocytosis | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002219-69 | Sponsor Protocol Number: CHUBX2019/49 | Start Date*: 2021-07-19 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Long-term iron chelation in the prevention of secondary degeneration after cerebral infarction | ||
Medical condition: Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001015-82 | Sponsor Protocol Number: ALXN1840-WD-302 | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric particip... | |||||||||||||
Medical condition: Wilson Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017354-12 | Sponsor Protocol Number: A6281297 | Start Date*: 2010-10-11 | |||||||||||
Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO ARM CROSS-OVER STUDY ASSESSING DYAD (SUBJECT AND CAREGIVER) AND ADULT SUBJECT PERCEPTION OF CONVENIENCE AND PREFERENCE OF THE NEWLY DEVELOPED GENOTROPIN M... | |||||||||||||
Medical condition: Subjects with Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) SK (Completed) DE (Completed) GB (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000691-42 | Sponsor Protocol Number: VAC52150EBL3001 | Start Date*: 2019-04-25 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola | |||||||||||||
Medical condition: Prevention of Ebola virus disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002895-42 | Sponsor Protocol Number: D6580C00003 | Start Date*: 2018-11-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomized, double blind, placebo-controlled, parallel group, multicentre, phase 2a study to assess target engagement, safety and tolerability of AZD4831 in patients with Heart Failure with prese... | |||||||||||||
Medical condition: Heart failure with preserved Ejection Fraction (HFpEF) and heart failure with mid-range Ejection Fraction (HFmrEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005079-17 | Sponsor Protocol Number: 06-IN-AK004 | Start Date*: 2007-02-19 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: An Open-Label, Multicenter, Multinational Study to Assess the Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-Ventilated Patients with Nosocomial Pne... | |||||||||||||
Medical condition: Nosocomial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000835-24 | Sponsor Protocol Number: D3690C00010 | Start Date*: 2007-08-01 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multi-centre, Double-blind, Double-Dummy, Placebo-controlled, Parallel Group, Randomised, Phase IIb Proof of Concept Study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatmen... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) AT (Completed) BE (Completed) BG (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004468-69 | Sponsor Protocol Number: TV1106-IMM-20001 | Start Date*: 2014-06-11 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries, Ltd. | |||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone (Genotropin®) Therapy in Treatment-Naive,... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) RO (Ongoing) GR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001787-10 | Sponsor Protocol Number: IG1407 | Start Date*: 2019-01-12 | |||||||||||
Sponsor Name:Instituto Grifols S.A. | |||||||||||||
Full Title: Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality | |||||||||||||
Medical condition: Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Completed) DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) DK (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004152-20 | Sponsor Protocol Number: AVA 102675 | Start Date*: 2007-11-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-t... | |||||||||||||
Medical condition: Mild-moderate Alzheimer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) SE (Prematurely Ended) BE (Completed) ES (Completed) GR (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) SK (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011790-32 | Sponsor Protocol Number: 09.0111p | Start Date*: 2010-03-18 |
Sponsor Name:Isala Klinieken Department Cardiology | ||
Full Title: Catheter ablation versus Amiodarone to prevent future shock episodes in patients with a defibrillator and a history of a myocardial infarction. | ||
Medical condition: The main objective of this study is to compare the occurrence of next ICD shock therapy for VT or VF in patients with hospital presentation for an ICD shock therapy for VT or VF, with a history of ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004992-21 | Sponsor Protocol Number: V72P10E1 | Start Date*: 2014-11-28 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l | ||
Full Title: A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10. | ||
Medical condition: Prophylaxis against invasive meningococcal disease | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004174-42 | Sponsor Protocol Number: A9451162 | Start Date*: 2015-04-06 |
Sponsor Name:Pfizer Japan Inc. | ||
Full Title: An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Subjects With Partial Seizures When Other Antiepileptics Do N... | ||
Medical condition: Epilepsy with partial seizures (including secondarily generalized seizures) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-004869-88 | Sponsor Protocol Number: HS2116100 | Start Date*: 2016-12-21 |
Sponsor Name:GlaxoSmithKline K.K. (GSK) | ||
Full Title: A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell t... | ||
Medical condition: Herpes simplex virus (HSV) infection before and after hematopoietic stem cell transplantation. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-002265-21 | Sponsor Protocol Number: 207702 | Start Date*: 2018-01-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A placebo-controlled, double-blind (sponsor open), randomised, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough | |||||||||||||
Medical condition: Chronic cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000833-38 | Sponsor Protocol Number: ISIS329993-CS6 | Start Date*: 2012-06-19 | |||||||||||
Sponsor Name:Isis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation | |||||||||||||
Medical condition: Atrial fibrillation (AF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000979-18 | Sponsor Protocol Number: AZ3100603 | Start Date*: 2005-06-21 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with... | ||
Medical condition: Alzheimer’s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SK (Completed) CZ (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002590-22 | Sponsor Protocol Number: NN9924-4338 | Start Date*: 2019-07-25 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002751-19 | Sponsor Protocol Number: 82160 | Start Date*: 2023-04-11 |
Sponsor Name:Amsterdam UMC | ||
Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients | ||
Medical condition: Inflammatory Bowel Diseases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
